Peptide library / Heart & blood / Ecallantide
Ecallantide
A 60 amino acid kallikrein blocker for attacks of hereditary angioedema.
Effects studied or claimed
What it is used or promoted for, and where each effect has actually been seen
- Acute attacks of hereditary angioedemaFDA approved
How it is thought to work
Ecallantide blocks plasma kallikrein, which stops the release of bradykinin, the driver of swelling.
What the evidence shows
Trials showed faster symptom relief than placebo.
Safety and unknowns
A boxed warning covers anaphylaxis, so it must be given by a healthcare professional.
Regulatory status
FDA-approved as Kalbitor in 2009.
Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.
More in Heart & blood
Elamipretide
FDA-approvedA four amino acid peptide that targets mitochondria, approved in 2025 for Barth syndrome.
Enlicitide
In clinical trialsAn investigational oral PCSK9 inhibitor from Merck that sharply lowers LDL cholesterol.
Desirudin
FDA-approvedA recombinant version of hirudin, a leech protein, used to prevent clots after hip surgery.
General information, not medical advice. Do not buy or inject unregulated peptides.